In the most recent trading session, Eli Lilly (LLY) closed at $822.27, indicating a -0.22% shift from the previous trading day.

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs ... which lowered the corporate tax rate in the US to 21% from 35%. If those policies aren’t extended, he said, “We’d have to re-look ...

As we continue to advance our Axiomer ADAR-mediated RNA editing platform and pipeline, ProQR is entering a pivotal phase of growth and ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...

Eli Lilly (LLY) stock dropped by 0.22%, underperforming the S&P 500’s 0.49% gain. Over the past month, the stock has fallen 4 ...

(CNN) — Eli Lilly, the maker of blockbuster weight loss ... which lowered the corporate tax rate in the US to 21% from 35%. If those policies aren’t extended, he said, “We’d have to ...

At the same time, based on the consensus FY2027 adj EPS estimates of $35.67, there remains an excellent upside potential of +73.5% to our long-term price target of $1,514.90 as well, with it ...